Akero Therapeutics is a biotechnology company. Akero's mission is to reverse the course of serious metabolic diseases and change patients’ lives. The company's dedicated team is laser-focused on reversing the NASH epidemic by restoring the metabolism of the body to a balanced state.
Its multi-modal drug, efruxifermin (EFX), mimics FGF21 to face the many facets of NASH, and clinical data suggests that it possesses the potential to become a foundational NASH monotherapy.
Akero is involved in R&D which is solely focused on developing medicines to reverse the escalating NASH epidemic, a disease that involves the whole body, and requires treatment of the imbalanced metabolism. This R&D approach is applied to address the underlying metabolic causes and the downstream pathological pathways leading to liver cirrhosis, liver failure and death.